Today is the Worst GLP1s+ Will Ever Be GLP1s+ More effective (5% to 22% weight loss and on their way to 25%+) More expansive disease management (diabetes, obesity, CVD, CKD, OSA, and studied for more) Less frequent (2x per day to 1x week and on their way to 1x/month to 1x/year?) Additional effective options in orals are on their way Insurance Coverage Medicare adding coverage for CVD (hopefully more diseases on the way as labels expand) Medicaid added 5 states in just 2023 Federal government added all employees and family members in 2023 Commercial employer coverage increased by 35% in 2023, with more employers considering it The Treat and Reduce Obesity Act (TROA) has been introduced in Congress to encourage Medicare coverage Costs Zepbound, a more effective drug, launched ~20-30% cheaper than Wegovy, with a savings card that put it at just over 1/3rd of the price at the time
[7] There is compelling evidence that some ME/CFS patients are low in methylation cycle metabolites, and there are some studies that provide direct evidence of methylation cycle dysregulation in ME/CFS
Brands like Ozempic (for diabetes) and Wegovy (for weight loss) together contributed an estimated $25.4 billion in global revenues in 2024, highlighting the immense commercial potential
Truthfully, its the most common method of taking all types of supplements and vitamins, such as Vitamin C and D
